Annovis Bio Inc. (NYSE: ANVS) announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses. Net proceeds are intended to support continued clinical development of buntanetap for Alzheimer's and Parkinson's disease, as well as working capital and general corporate purposes.
The offering is significant as it provides Annovis with additional capital to advance buntanetap, its lead drug candidate, through clinical trials. Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focusing on developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The successful completion of this offering could accelerate the timeline for buntanetap's development, potentially bringing a new therapeutic option to patients suffering from these devastating conditions.
The implications of this funding extend beyond the company itself. Alzheimer's and Parkinson's diseases affect millions worldwide, with current treatments primarily addressing symptoms rather than underlying causes. Buntanetap's unique mechanism of action, targeting multiple neurotoxic proteins, offers hope for disease-modifying therapies. If successful, it could significantly impact patient outcomes and reduce the burden on healthcare systems.
Investors should note that the offering involves warrants, which could lead to future dilution. However, the capital infusion is crucial for Annovis to continue its research and development activities. For more information, the full press release is available at https://ibn.fm/KRpCW.
Annovis Bio is publicly traded on the NYSE under the ticker symbol ANVS. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
